Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Part of paid clinical trials in San Francisco, California.

Sponsor
UNC Lineberger Comprehensive Cancer Center
Study ID
NCT01573702
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stereotactic Radiosurgery — PROCEDURE
    21 Gy daily for 5 days
  • Erlotinib — DRUG
    150mg once daily

Study Details

\- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy

Key Dates

First listed
Apr 9, 2012
Start date
Dec 11, 2012
Status verified
Dec 2020
Primary completion
Mar 15, 2019
Completion
Mar 15, 2019

Study Design

Enrollment
32 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Stereotactic Radiosurgery Followed by Erlotinib
    Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib

Primary Outcome Measure

Percentage of Participants With Progression Free Survival [ Time Frame: 3 months after Initiation of Stereostatic Radiotherapy ]

Locations (8)

FacilityCityStateZIPSite coordinators
University of California at San FranciscoSan FranciscoCalifornia94115-
University of Colorado Cancer CenterAuroraColorado80045-
Lineberger Comprehensive Cancer CenterChapel HillNorth Carolina27599-
East Carolina UniversityGreenvilleNorth Carolina27834-
STO Taussig Cancer Center; Cleveland ClinicClevelandOhio44195-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
University of Pittsburgh Medical CenterPittsburghPennsylvania15232-
Swedish Cancer InstituteSeattleWashington98104-

Find similar trials in San Francisco, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of California at San Francisco· San Francisco, CAUniversity of Colorado Cancer Center· Aurora, COLineberger Comprehensive Cancer Center· Chapel Hill, NCEast Carolina University· Greenville, NCSTO Taussig Cancer Center; Cleveland Clinic· Cleveland, OHFox Chase Cancer Center· Philadelphia, PA

Related Studies